GENETIC POLYMORPHISM OF REVERSE TRANSCRIPTASE AND PROTEASE ASSOCIATED WITH THE ANTIRETROVIRAL (ARV) INEFFICIENCY IN PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE-2 (HIV-2) IN ABIDJAN, CÃ”TE Dâ€™IVOIRE
Objectives: To analyse the genetic polymorphism of reverse transcriptase and protease genes in patients living with HIV-2, to search for possible mutations preventing the effectiveness of antiretroviral drugs (ARVs).
Methods: RNA Viral was extracted after lysis of the virus particles and purified on filter columns (Qiagen). After their extraction, DNA fragments were amplified by the method of reverse transcription/polymerase chain reaction (RT/PCR) on one hand and by the PCR method enchase on the other hand. The study of genetic polymorphisms in reverse transcriptase and protease was performed after sequencing of amplicons.
Results: A significant polymorphism was observed in positions involved in resistance to antiretrovirals. The most frequent was mutations M 46 I, M 36 I/V, V82I, L 89 I on protease and Y 181 I, Y 188 L, G 190A on reverse transcriptase.
Conclusion: Polymorphic mutations were observed in the genes of the protease and reverse transcriptase and could be involved in the HIV-2 resistance to antiretrovirals (ARVs). It would be desirable to do the quantification of DNA provirus of HIV-2 in the other for a durable therapeutic monitoring of patients having HIV-2.
Keywords: Human Immunodeficiency Virus (HIV-2), Reverse transcriptase, Protease, Abidjan, CÃ´te dâ€™Ivoire.
2. La stratÃ©gie mondiale du secteur de la santÃ© sur le VIH/SIDA 2011â€“2015: IntÃ©rimaire des progrÃ¨s ; 2014. p. 1-41.
3. Anglemyer A, Rutherford GW, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane database of systematic reviews. The Cochrane library; 2011. p. 1-44.
4. Rispel LC, Metcalf CA, Cloete A, Reddy V, Lombard C. HIV prevalence and risk practices among men who have sex with men in two South African cities. J Acquired Immune Defic Syndr 2011;57:69â€“76.
5. Myron S, Cohen MD, Ying Q, Chen PhD, Marybeth-McCauley MPH, Theresa G, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (NEJM) 2011;365:493â€“505.
6. Long L, Brennan A, Fox MP, Ndibongo B, Jaffray I, Sanne I, et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observation cohort. PLoS Medicine 2011;8:1-10.
7. Anna RC, Michela M, Giulio P, Bruni R, Iudicone P, Costantino A, et al. Improving HIV-2 Detection by a combination of serological and nucleic acid amplification test assays. J Clin Microbiol 2010;48:2902â€“8.
8. Hallett TB, Alsallaq RA, Baeten JM, Weiss H, Celum C, Gray R, et al. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. Sexually Transmitted Infections (STI) 2011;87:88â€“93.
9. Rosen S, Fox M. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011;8:1-16.
10. Dahoma M, Johnston LG, Holman A, Miller LA, Mussa M, Othman A, et al. HIV and related risk behavior among men who have sex with men in Zanzibar, Tanzania: results of a behavioral surveillance survey. AIDS Behaviour 2011;15:186â€“92.
11. Merrigan M, Azeez A, Afolabi B, Chabikuli ON, Onyekwena O, Eluwa G, et al. HIV prevalence and risk behaviours among men having sex with men in Nigeria. Sexually Transmitted Infections (STI) 2011;87:65â€“70.
12. Thompson JD, Higgins DG, Gibson TJ, Clustal W. Improving sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-780.
13. Cohen J. High turnover of HIV in blood revealed by new studies. Science 1995;267:179.
14. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harbor Perspect Med 2011;1:1-23.
15. Ntemgwa M, Toni TA, Brenner BG, Camacho RJ, Wainberg MA. Antiretroviral drug resistance in human immunodeficiency virus type 2. Am Soc Microbiol (ASM) 2009;53:3611-9.
16. Sabelle J. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the gambia and emergence of drug-resistant variants. J Clin Microbiol (JCM) 2009;47:2200â€“8.
17. Kevin P, Sabelle J, Sarah LRJ, De Silva TL. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat 2011. doi.org/10.1155/2011/463704. [Article in Press].
18. Wainberg MA, Brenner BG. Role of HIV subtype diversity in the development of resistance to antiviral drugs. Viruses 2010;2:2493-508.
19. Ana T, Carmen de M, Estrella C, Carmen R, Patricia P, Rafael B, et al. Drug resistance mutations in patients infected with HIV-2 living in Spain. J Antimicrob Chemother 2011;66:1484â€“8.
20. Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, et al. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resist Updates 2011;14:141-9.